SuperworthAcadia Pharmaceuticals shares outstanding ACAD
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 172.9M
- On a year earlier
- +2.5%
- more shares
Acadia Pharmaceuticals had 172.9M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 2.5% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 172.2M | +3% |
| FY2024 | 167M | +1% |
| FY2023 | 164.8M | +2% |
| FY2022 | 162M | −1% |
| FY2021 | 163M | +2% |
| FY2020 | 159.3M | +3% |
| FY2019 | 154.5M | +17% |
| FY2018 | 131.6M | +6% |
| FY2017 | 124.1M | +2% |
| FY2016 | 121.2M | +20% |
| FY2015 | 101.2M | +4% |
| FY2014 | 97.4M | +7% |
| FY2013 | 91M | +50% |
| FY2012 | 60.6M | +15% |
| FY2011 | 52.8M | +34% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 172.9M | +2% | |
| Q1 FY26 | 172.7M | +3% | |
| Q4 FY25 | 172.2M | +3% | |
| Q3 FY25 | 170.7M | +3% | |
| Q2 FY25 | 168.7M | +2% | |
| Q1 FY25 | 167.7M | +1% | |
| Q4 FY24 | 167M | +1% | |
| Q3 FY24 | 166.2M | +1% | |
| Q2 FY24 | 166.2M | +1% | |
| Q1 FY24 | 166.6M | +3% | |
| Q4 FY23 | 164.8M | +2% | |
| Q3 FY23 | 164.2M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Acadia Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.